CY1120742T1 - Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων - Google Patents
Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεωνInfo
- Publication number
- CY1120742T1 CY1120742T1 CY181101037T CY181101037T CY1120742T1 CY 1120742 T1 CY1120742 T1 CY 1120742T1 CY 181101037 T CY181101037 T CY 181101037T CY 181101037 T CY181101037 T CY 181101037T CY 1120742 T1 CY1120742 T1 CY 1120742T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lxr
- disorders
- treatment
- conditions
- skin diseases
- Prior art date
Links
- 208000017520 skin disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 238000004353 relayed correlation spectroscopy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606160P | 2012-03-02 | 2012-03-02 | |
| PCT/US2013/028438 WO2013130892A1 (en) | 2012-03-02 | 2013-02-28 | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120742T1 true CY1120742T1 (el) | 2019-12-11 |
Family
ID=49083313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181101037T CY1120742T1 (el) | 2012-03-02 | 2018-10-08 | Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8987318B2 (enExample) |
| EP (2) | EP2820013B9 (enExample) |
| JP (2) | JP6378630B2 (enExample) |
| KR (1) | KR102112879B1 (enExample) |
| CN (1) | CN104284893B (enExample) |
| AU (1) | AU2013225840B2 (enExample) |
| BR (1) | BR112014021515A2 (enExample) |
| CA (1) | CA2866113C (enExample) |
| CY (1) | CY1120742T1 (enExample) |
| DK (1) | DK2820013T3 (enExample) |
| ES (1) | ES2691079T3 (enExample) |
| HR (1) | HRP20181623T1 (enExample) |
| HU (1) | HUE040231T2 (enExample) |
| IL (1) | IL234413B (enExample) |
| LT (1) | LT2820013T (enExample) |
| MX (1) | MX361349B (enExample) |
| NZ (1) | NZ629636A (enExample) |
| PL (1) | PL2820013T3 (enExample) |
| PT (1) | PT2820013T (enExample) |
| RS (1) | RS57863B9 (enExample) |
| SG (2) | SG11201405378VA (enExample) |
| SI (1) | SI2820013T1 (enExample) |
| SM (1) | SMT201800630T1 (enExample) |
| TR (1) | TR201815013T4 (enExample) |
| WO (1) | WO2013130892A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2820013T3 (pl) | 2012-03-02 | 2019-01-31 | Ralexar Therapeutics, Inc. | Modulatory receptorów X wątroby (LXR) do leczenia chorób, zaburzeń i stanów skórnych |
| ES2694001T3 (es) * | 2013-03-15 | 2018-12-17 | Bristol-Myers Squibb Company | Moduladores de LXR |
| CN104151300B (zh) * | 2013-05-15 | 2018-07-13 | 中国医学科学院医药生物技术研究所 | 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途 |
| MX2016002930A (es) * | 2013-09-04 | 2016-12-02 | Ralexar Therapeutics Inc | Moduladores del receptor x hepatico (lxr). |
| SI3041835T1 (sl) * | 2013-09-04 | 2020-09-30 | Ellora Therapeutics, Inc. | Modulatorji jetrnih X receptorjev (LXR) |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| WO2017115319A2 (en) | 2015-12-30 | 2017-07-06 | Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) | Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| CN114126618A (zh) | 2019-07-15 | 2022-03-01 | 诺华股份有限公司 | 用肝脏x受体激动剂治疗睑板腺功能障碍的方法 |
| EP4073025B1 (en) | 2019-12-13 | 2024-03-27 | Inspirna, Inc. | Metal salts and uses thereof |
| WO2022249006A1 (en) * | 2021-05-24 | 2022-12-01 | Novartis Ag | Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1199771A (en) * | 1915-07-01 | 1916-10-03 | Bates Valve Bag Co | Wire-twisting machine. |
| WO2002024632A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| MXPA04011690A (es) | 2002-05-24 | 2005-03-31 | Pharmacia Corp | Moduladores de receptor x de higado de sulfona. |
| US6900244B2 (en) | 2002-05-24 | 2005-05-31 | Pharmacia Corporation | Anilino liver X-receptor modulators |
| ES2361924T3 (es) | 2002-12-20 | 2011-06-24 | X-Ceptor Therapeutics, Inc. | Derivados de isoquinolinona y su uso como agentes terapéuticos. |
| JP2006193426A (ja) | 2003-09-05 | 2006-07-27 | Sankyo Co Ltd | 置換された縮環ピリミジン−４（３ｈ）−オン化合物 |
| WO2005113499A1 (ja) | 2004-05-20 | 2005-12-01 | Sankyo Company, Limited | インドール化合物 |
| TW200606133A (en) | 2004-06-30 | 2006-02-16 | Sankyo Co | Substituted benzene compounds |
| BRPI0514017A (pt) | 2004-08-03 | 2008-05-27 | Wyeth Corp | indazóis úteis no tratamento de doenças cardiovasculares |
| US20070060589A1 (en) * | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| WO2006109633A1 (ja) | 2005-04-07 | 2006-10-19 | Daiichi Sankyo Company, Limited | 置換インドール化合物 |
| US7213797B2 (en) | 2005-05-20 | 2007-05-08 | Garland Jerome Gaskins | Deck board straightener |
| CA2613517A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
| CN101248049B (zh) * | 2005-06-27 | 2013-08-28 | 埃克塞利希斯专利有限责任公司 | 咪唑类lxr调节剂 |
| PT1940786E (pt) | 2005-09-16 | 2010-10-04 | Arrow Therapeutics Ltd | Derivados de bifenilo e sua utilização no tratamento de hepatite c |
| WO2007034279A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| AU2006337682A1 (en) | 2005-11-14 | 2007-08-16 | Irm Llc | Compounds and compositions as LXR modulators |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| TW200825054A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
| AU2007333194A1 (en) | 2006-12-08 | 2008-06-19 | Exelixis, Inc. | LXR and FXR modulators |
| EP2137158A4 (en) * | 2007-02-28 | 2012-04-18 | Methylgene Inc | LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS) |
| CN101679311A (zh) | 2007-05-18 | 2010-03-24 | 惠氏公司 | 喹唑啉化合物 |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| RU2454412C2 (ru) | 2007-08-13 | 2012-06-27 | Ф.Хоффманн-Ля Рош Аг | Новые пиперазинамидные производные |
| CN101945871A (zh) | 2007-12-21 | 2011-01-12 | 惠氏有限责任公司 | 咪唑并[1，2-a]吡啶化合物 |
| BRPI0821315A2 (pt) | 2007-12-21 | 2019-09-24 | Wyeth Llc | compostos benzimidazol |
| JP2011520884A (ja) * | 2008-05-13 | 2011-07-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を変調するスルホン化合物 |
| US8063088B2 (en) | 2008-06-11 | 2011-11-22 | Hoffmann-La Roche Inc. | Imidazolidine derivatives |
| JP2012508250A (ja) | 2008-11-07 | 2012-04-05 | ワイス・エルエルシー | キノキサリン系のｌｘｒモジュレーター |
| EP2367801A1 (en) | 2008-11-19 | 2011-09-28 | Wyeth LLC | Polar quinazolines as liver x receptors ( lxrs ) modulators |
| AU2009330233A1 (en) | 2008-12-22 | 2011-07-07 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| US20120058133A1 (en) * | 2009-02-19 | 2012-03-08 | President And Fellows Of Harvard College | Inhibition of trna synthetases and therapeutic applications thereof |
| EP2398474A4 (en) | 2009-02-23 | 2012-12-05 | Presidio Pharmaceuticals Inc | HCV NS5A SHEMMER |
| AU2010254082B2 (en) | 2009-05-28 | 2015-01-29 | Exelixis, Inc. | LXR modulators |
| GB0919757D0 (en) | 2009-11-12 | 2009-12-30 | Johnson Matthey Plc | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| US20120263646A1 (en) | 2009-10-15 | 2012-10-18 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
| EP2604602A4 (en) * | 2010-08-11 | 2013-12-18 | Taisho Pharmaceutical Co Ltd | HETEROARYL PYRAZOLE DERIVATIVE |
| CA2809830C (en) * | 2010-08-27 | 2019-09-10 | Calcimedica, Inc. | Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| PL2820013T3 (pl) | 2012-03-02 | 2019-01-31 | Ralexar Therapeutics, Inc. | Modulatory receptorów X wątroby (LXR) do leczenia chorób, zaburzeń i stanów skórnych |
| EP4218935A1 (en) | 2012-08-13 | 2023-08-02 | The Rockefeller University | Lxrbeta agonist for the treatment of cancer |
| MX2016002930A (es) | 2013-09-04 | 2016-12-02 | Ralexar Therapeutics Inc | Moduladores del receptor x hepatico (lxr). |
| SI3041835T1 (sl) | 2013-09-04 | 2020-09-30 | Ellora Therapeutics, Inc. | Modulatorji jetrnih X receptorjev (LXR) |
-
2013
- 2013-02-28 PL PL13754329T patent/PL2820013T3/pl unknown
- 2013-02-28 MX MX2014010537A patent/MX361349B/es active IP Right Grant
- 2013-02-28 NZ NZ629636A patent/NZ629636A/en not_active IP Right Cessation
- 2013-02-28 WO PCT/US2013/028438 patent/WO2013130892A1/en not_active Ceased
- 2013-02-28 CN CN201380018482.7A patent/CN104284893B/zh not_active Expired - Fee Related
- 2013-02-28 BR BR112014021515-4A patent/BR112014021515A2/pt active Search and Examination
- 2013-02-28 HU HUE13754329A patent/HUE040231T2/hu unknown
- 2013-02-28 EP EP13754329.4A patent/EP2820013B9/en active Active
- 2013-02-28 DK DK13754329.4T patent/DK2820013T3/en active
- 2013-02-28 KR KR1020147027825A patent/KR102112879B1/ko not_active Expired - Fee Related
- 2013-02-28 CA CA2866113A patent/CA2866113C/en not_active Expired - Fee Related
- 2013-02-28 SI SI201331198T patent/SI2820013T1/sl unknown
- 2013-02-28 RS RS20181179 patent/RS57863B9/sr unknown
- 2013-02-28 AU AU2013225840A patent/AU2013225840B2/en not_active Ceased
- 2013-02-28 LT LTEP13754329.4T patent/LT2820013T/lt unknown
- 2013-02-28 SM SM20180630T patent/SMT201800630T1/it unknown
- 2013-02-28 ES ES13754329.4T patent/ES2691079T3/es active Active
- 2013-02-28 JP JP2014560060A patent/JP6378630B2/ja not_active Expired - Fee Related
- 2013-02-28 SG SG11201405378VA patent/SG11201405378VA/en unknown
- 2013-02-28 EP EP18182346.9A patent/EP3441390A1/en not_active Withdrawn
- 2013-02-28 TR TR2018/15013T patent/TR201815013T4/tr unknown
- 2013-02-28 HR HRP20181623TT patent/HRP20181623T1/hr unknown
- 2013-02-28 SG SG10201607345YA patent/SG10201607345YA/en unknown
- 2013-02-28 PT PT13754329T patent/PT2820013T/pt unknown
-
2014
- 2014-09-01 IL IL234413A patent/IL234413B/en active IP Right Grant
- 2014-09-02 US US14/474,490 patent/US8987318B2/en not_active Expired - Fee Related
-
2015
- 2015-02-12 US US14/621,255 patent/US9637481B2/en not_active Expired - Fee Related
-
2017
- 2017-04-03 US US15/477,140 patent/US20170334897A1/en not_active Abandoned
-
2018
- 2018-04-18 US US15/956,389 patent/US20180370959A1/en not_active Abandoned
- 2018-08-02 JP JP2018145589A patent/JP6800922B2/ja not_active Expired - Fee Related
- 2018-10-08 CY CY181101037T patent/CY1120742T1/el unknown
-
2020
- 2020-05-13 US US15/931,403 patent/US20210101895A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120742T1 (el) | Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1124055T1 (el) | Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες | |
| CY1124918T1 (el) | Ρυθμιστες ccr2 | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
| CY1124595T1 (el) | Ρυθμιση δραστικοτητας συμπληρωματος | |
| CY1124059T1 (el) | Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa | |
| CY1121989T1 (el) | Φαρμακοτεχνικες μορφες αντισωματων | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| CY1117745T1 (el) | Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης | |
| JO3474B1 (ar) | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| UY34542A (es) | ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?. | |
| MX387596B (es) | Degradadores selectivos del receptor de estrógeno y sus usos. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| GT201500069A (es) | Piridinonas bicìclicas novedosas | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| CO6771450A2 (es) | Ureas asimétricas y usos médicos de las mismas | |
| CY1121326T1 (el) | Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες | |
| CO7151509A2 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 |